BioVectra and PhaseBio Discuss Creating an Optimal Partnership

Liquids & Semisolids

What Makes a Great Liquid Oral Dose CDMO?

Rob Terry

TriRx Pharmaceutical Services

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

LAI Formulation

The Formulation Science Behind Extended Drug Release

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

Outsourcing

Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?

Pharma's Almanac

Tech Transfer

Why Successful Scale-Up and Transfer Capabilities Increasingly Determine Outsourcing Success

Pharma's Almanac

LNP Strategy

Building Better RNA Medicines Through Smarter LNP Formulation Strategy

Aula Al Muslim, Ph.D.

Recipharm Advanced Bio

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA